SalaryGuide
AboutPricingFor Employers

Marketing jobs

4 marketing jobs

Immunome, Inc. logo
12 days ago

Senior Manager / Associate Director, Peer-to-Peer and Congress Marketing

Immunome, Inc.

Bothell, WA (On-site)Full time$175K/yr – $232K/yr
Immunome, Inc. logo
4 months ago

Associate Director / Director, Patient Marketing

Immunome, Inc.

Bothell, WA (On-site)Full time$183K/yr – $230K/yr
Immunome, Inc. logo
4 months ago

Senior Manager / Associate Director, HCP NPP Omnichannel Marketing

Immunome, Inc.

Bothell, WA (On-site)Full time$190K/yr – $230K/yr
Immunome, Inc. logo
4 months ago

Director, HCP Marketing

Immunome, Inc.

Bothell, WA (On-site)Full time$198K/yr – $252K/yr

All marketing roles in the US

Get alerts for this search

All marketing roles in the US

Get alerts for this search

4 jobs
Immunome, Inc. logo

Senior Manager / Associate Director, Peer-to-Peer and Congress Marketing

Immunome, Inc.

Bothell, WA (On-site)

$175K/yr - $232K/yrIn-houseFull-timeSenior level5+ years exp.
12 days ago
Immunome, Inc. logo

Associate Director / Director, Patient Marketing

Immunome, Inc.

Bothell, WA (On-site)

$183K/yr - $230K/yrIn-houseFull-timeDirector/executive7+ years exp.
4 months ago
Immunome, Inc. logo

Senior Manager / Associate Director, HCP NPP Omnichannel Marketing

Immunome, Inc.

Bothell, WA (On-site)

$190K/yr - $230K/yrIn-houseFull-timeSenior level5+ years exp.
4 months ago
Immunome, Inc. logo

Director, HCP Marketing

Immunome, Inc.

Bothell, WA (On-site)

$198K/yr - $252K/yrIn-houseFull-timeDirector/executive10+ years exp.
4 months ago
Immunome, Inc. logo
Immunome, Inc.

Senior Manager / Associate Director, Peer-to-Peer and Congress Marketing

Bothell, WA (On-site)

$175K/yr – $232K/yrSenior Level5+ years expFull time

Posted 12 days ago

Top 1% of applicants do these two things.

The other 99% submit and hope. You're about to do something different.

Job Summary

Own and drive end-to-end P2P and congress programs to elevate HCP engagement, with a focus on speaker bureaus, advisory boards, and external partnerships in support of oncology launches.

  • Lead P2P strategy aligned to brand goals and launch priorities
  • Manage speaker bureaus, advisory boards, and congress planning
  • Develop educational programs and in-office materials for field delivery

Job Description

Responsibilities

  • Lead the development and execution of the P2P strategy aligned to brand objectives and launch priorities.
  • Design and manage speaker bureau programs, including content development, speaker training, performance tracking, and partnership with the sales team to ensure execution excellence.
  • Identify and execute P2P education opportunities (e.g., product theaters, satellite programs) to expand reach and enhance impact through innovative formats.
  • Own end-to-end execution of advisory boards, including objective setting, logistics , content development, stakeholder alignment, and synthesis of actionable insights.
  • Implement and manage third-party programs and external engagements to systematically gather HCP insights and inform brand strategy.
  • Develop HCP-facing derivative materials to support in-office and local program delivery.
  • Own end-to-end congress strategy for key national and regional meetings.
  • Lead the development of corporate booth strategy, design, and content for major medical congresses, ensuring alignment with corporate and brand objectives .
  • Develop field-facing congress tools and materials to support sales-led regional and local conferences.
  • Establish and cultivate strategic partnerships with key national societies, identifying opportunities to enhance presence and drive brand awareness .

Requirements

  • Bachelor’s degree required ; advanced degree (e.g., PharmD, MBA) preferred.
  • A minimum of 5+ years of experience in pharmaceutical, biotech, or healthcare marketing, or equivalent; oncology experience preferred.
  • Oncology launch experience required .
  • Proven track record in speaker bureau management, peer-to-peer program and advisory board execution, and congress planning.
  • Strong understanding of MLR/PRC processes, claims substantiation, and OPDP regulations.
  • Demonstrated ability to thrive in a fast-paced biotech environment.
  • Ability to travel ≥30%, including occasional weekends.
  • Knowledge and Skills: Deep understanding of HCP engagement strategies, including live, virtual, and hybrid formats.
  • Knowledge and Skills: Strong analytical and problem-solving skills, with the ability to leverage market research and performance data to inform decisions and optimize impact.
  • Knowledge and Skills: Strong project management and operational execution skills; able to manage multiple workstreams and launch-critical deadlines in a fast-paced environment.
Immunome, Inc. logo

Immunome, Inc.

2.5 Glassdoor

Immunome is a clinical-stage targeted oncology company committed to developing first-in-class and best-in-class targeted therapies designed to improve outcomes for cancer patients. We are advancing an innovative portfolio of therapeutics, drawing on leadership that previously played key roles in the design, development, and commercialization of cutting-edge targeted cancer therapies, including antibody-drug conjugate therapies (ADCs). Our most advanced pipeline programs are varegacestat (formerly AL102), a gamma secretase inhibitor which is currently in a Phase 3 trial for treatment of desmoid tumors; IM-1021, a ROR1-targeted ADC which is currently in a Phase 1 trial; and IM-3050, a FAP-targeted radioligand, which recently received IND clearance. Our pipeline also includes IM-1617, IM-1335, and IM-1340, all of which are preclinical ADCs pursuing undisclosed targets with expression in multiple solid tumors.

Founded in 2008
Bothell, Washington, USA
187 employees (3 in marketing)
www.immunome.com
58% recommend to a friend

Traffic Signals

Monthly Visitors
12.4K
Traffic Source Mix
Search
31.1%
Direct
45.6%
Referral
6.5%
Social
15.2%
Paid
1.5%

Headcount Trend

Current headcount: ~191

Marketing Team

Marketing Team Size
3 (2% of company)
Marketing Roles Posted (Last 30 Days)
1

Funding

Total Funding
$998.9M
Last Raise
$400M
Post IPO Equity, 3 months ago

Funding History

  • Dec 2025
    Post IPO Equity • $400M
  • Jan 2025
    Post IPO Equity • $150M
  • Feb 2024
    Post IPO Equity • $230M

Recent News

Immunome (NASDAQ:IMNM) Upgraded at Wall Street Zen
Nov 22, 2025 • Defense World
Immunome stock hits 52-week high at $18.79
Nov 20, 2025 • Investing.com
Is Immunome Inc. stock a safe haven asset - GDP Growth & Weekly Top Gainers Trade List
Nov 19, 2025 • newser.com
Is Immunome Inc. stock bottoming out - 2025 Bull vs Bear & Risk Controlled Stock Pick Alerts
Nov 19, 2025 • newser.com
Immunome (NASDAQ:IMNM) Stock Price Expected to Rise, Stephens Analyst Says
Nov 19, 2025 • Defense World
Lake Street Sticks to Their Buy Rating for Immunome (IMNM)
Nov 19, 2025 • The Globe and Mail
A new trading data show Immunome Inc (IMNM) is showing positive returns.
Nov 18, 2025 • Setenews
Immunome (NASDAQ:IMNM) Hits New 1-Year High on Analyst Upgrade
Nov 18, 2025 • Defense World
Stephens raises Immunome stock price target to $33 on varegacestat potential
Nov 17, 2025 • Investing.com Nigeria
Immunome price target raised to $33 from $25 at Stephens
Nov 17, 2025 • TipRanks
Is Immunome’s (IMNM) Improved Efficiency a Sign of Lasting Strength in the Biotech Race?
Nov 16, 2025 • simplywall.st
Historical volatility pattern of Immunome Inc. visualized - Quarterly Trade Summary & Real-Time Sentiment Analysis
Nov 15, 2025 • newser.com
Immunome stock hits 52-week high at 17.89 USD
Nov 12, 2025 • Investing.com
Immunome, Inc. Reports Q3 2025 Financial Results
Nov 10, 2025 • TipRanks
Immunome Stays Confident Despite Heavy Losses And Bold Spending
Nov 7, 2025 • Finimize
Immunome Reports Third Quarter 2025 Financial Results and Provides Business Update
Nov 6, 2025 • Business Wire
Immunome, Inc. Hits New 52-Week High of $17.87
Nov 3, 2025 • Markets Mojo
Immunome stock hits 52-week high at 17.34 USD
Nov 3, 2025 • Investing.com
Immunome to Present at 2nd Annual Guggenheim Healthcare Innovation Conference
Nov 2, 2025 • BioSpace
Immunome’s Phase 1 Cancer Study: A Potential Game-Changer?
Oct 27, 2025 • TipRanks
Evaluating Immunome Inc. with trendline analysis - Weekly Trade Summary & Safe Entry Momentum Tips
Oct 25, 2025 • newser.com
Evaluating Immunome Inc. with trendline analysis - Day Trade & AI Driven Stock Price Forecasts
Oct 25, 2025 • newser.com
How Immunome Inc. stock benefits from tech adoption - 2025 Valuation Update & High Conviction Buy Zone Alerts
Oct 25, 2025 • newser.com
What technical signals suggest for Immunome Inc. stock - Market Sentiment Review & Verified Momentum Watchlists
Oct 25, 2025 • newser.com
How Immunome Inc. stock benefits from tech adoption - Weekly Stock Report & High Accuracy Trade Alerts
Oct 25, 2025 • newser.com
Evaluating Immunome Inc. with trendline analysis - Weekly Trade Review & Capital Efficient Trading Techniques
Oct 25, 2025 • newser.com
How Immunome Inc. stock performs in rate cut cycles - July 2025 Drop Watch & Low Drawdown Investment Strategies
Oct 25, 2025 • newser.com
Evaluating Immunome Inc. with trendline analysis - 2025 Market WrapUp & Long-Term Capital Growth Strategies
Oct 25, 2025 • newser.com
How Immunome Inc. stock benefits from tech adoption - Market Trend Review & Free Daily Entry Point Trade Alerts
Oct 24, 2025 • newser.com
Can machine learning forecast Immunome Inc. recovery - 2025 Growth vs Value & Free Risk Controlled Daily Trade Plans
Oct 24, 2025 • newser.com
Immunome, Inc. (IMNM) Stock Analysis: A Biotech Contender With A 49% Potential Upside
Oct 24, 2025 • DirectorsTalk Interviews
Immunome’s ADC payload shows promise against cancer resistance By Investing.com
Oct 24, 2025 • Investing.com Australia
Immunome’s ADC payload shows promise against cancer resistance
Oct 23, 2025 • Investing.com
Immunome (IMNM) Unveils Promising Data on Novel ADC Payload HC74
Oct 23, 2025 • GuruFocus
Immunome’s ADC payload shows promise against cancer resistance By Investing.com
Oct 23, 2025 • Investing.com UK
Immunome Presents Preclinical Data Showing Proprietary TOP1i ADC Payload HC74 Overcomes Multiple Mechanisms of ADC Resistance
Oct 23, 2025 • The Joplin Globe
Can machine learning forecast Immunome Inc. recovery - 2025 Market Trends & Fast Entry High Yield Stock Tips
Oct 23, 2025 • newser.com
Chart overlay techniques for tracking Immunome Inc. - July 2025 Summary & Real-Time Market Sentiment Reports
Oct 23, 2025 • newser.com
Immunome Presents Preclinical Data Showing Proprietary TOP1i ADC Payload HC74 Overcomes Multiple Mechanisms of ADC Resistance
Oct 23, 2025 • Business Wire
Immunome stock hits 52-week high, reaching 17.27 USD By Investing.com
Oct 23, 2025 • Investing.com Philippines
Immunome stock hits 52-week high, reaching 17.27 USD
Oct 22, 2025 • Investing.com India
Immunome, Inc. Hits New 52-Week High at USD 17.32
Oct 22, 2025 • Markets Mojo
Immunome stock hits 52-week high, reaching 17.27 USD
Oct 22, 2025 • Investing.com
Can momentum traders help lift Immunome Inc. - 2025 Winners & Losers & Real-Time Volume Trigger Notifications
Oct 21, 2025 • newser.com
What moving averages say about Immunome Inc. - 2025 Geopolitical Influence & Free Real-Time Volume Trigger Notifications
Oct 21, 2025 • newser.com
Evaluating Immunome Inc. with trendline analysis - Quarterly Profit Review & Reliable Price Action Trade Plans
Oct 21, 2025 • newser.com
Is Immunome Inc. stock bottoming out - 2025 Year in Review & Real-Time Buy Zone Alerts
Oct 20, 2025 • newser.com
What moving averages say about Immunome Inc. - Quarterly Performance Summary & Expert Curated Trade Ideas
Oct 20, 2025 • newser.com
Can machine learning forecast Immunome Inc. recovery - July 2025 Setups & Detailed Earnings Play Alerts
Oct 20, 2025 • newser.com
Is Immunome Inc. stock attractive for income investors - Weekly Trade Recap & Free Risk Controlled Daily Trade Plans
Oct 18, 2025 • nchmf.gov.vn
Immunome, Inc. Hits Day High with 15.96% Surge in Stock Price
Oct 16, 2025 • Markets Mojo
Immunome, Inc. Hits New 52-Week High at $16.40
Oct 15, 2025 • Markets Mojo
Immunome stock hits 52-week high at 15.19 USD
Oct 15, 2025 • Investing.com
You might want to take a look at Immunome Inc (IMNM) now
Oct 14, 2025 • Setenews
Immunome, Inc. Hits Day High with 16.4% Surge in Stock Price
Oct 8, 2025 • Markets Mojo
Immunome, Inc. Experiences Revision in Stock Evaluation Amid Strong Market Performance
Oct 8, 2025 • Markets Mojo
A new trading data show Immunome Inc (IMNM) is showing positive returns.
Oct 7, 2025 • Setenews
Immunome, Inc. Hits Day High with Strong 7.93% Intraday Surge
Oct 6, 2025 • Markets Mojo
Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Oct 2, 2025 • Business Wire
Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Oct 2, 2025 • Caledonian Record
Immunome, Inc. Hits Day High with Strong 9.57% Intraday Surge
Sep 29, 2025 • Markets Mojo
Goldman Sachs Sees Positive Outlook for Immunome with $26 Price Target
Sep 28, 2025 • timothysykes.com
Immunome Secures Strategic Partnerships, Boosts Market Potential
Sep 27, 2025 • StocksToTrade
Will Immunome's (IMNM) Antibody Collaboration Refocus Its Pipeline Expansion Strategy?
Sep 27, 2025 • Yahoo Finance
Immunome Stock On the Rise Amid Strategic Collaborations
Sep 27, 2025 • timothysykes.com
Immunome (IMNM) Surges 6.1%: Is This an Indication of Further Gains?
Sep 25, 2025 • Yahoo Finance
Stocks With Rising Relative Strength: Immunome
Sep 25, 2025 • Investor's Business Daily
Immunome stock a ‘buy’ on ‘rich pipeline’ of oncology therapeutics: analysts
Sep 23, 2025 • Proactive financial news
Goldman Sachs initiates coverage on Immunome stock with Buy rating
Sep 22, 2025 • Investing.com
Goldman Sachs Initiates Coverage on Immunome (IMNM) with 'Buy' R
Sep 22, 2025 • GuruFocus
Infinimmune partners with Immunome on antibody discovery
Sep 18, 2025 • Investing.com
Infinimmune Announces Research Collaboration with Immunome
Sep 18, 2025 • Business Wire
Infinimmune Announces Research Collaboration with Immunome
Sep 18, 2025 • Yahoo Finance
Immunome (IMNM) Enters Collaboration with Infinimmune for Antibo
Sep 18, 2025 • GuruFocus
Immunome announces novel antibody collaboration with Infinimmune
Sep 18, 2025 • thefly.com
Infinimmune Announces Research Collaboration with Immunome
Sep 18, 2025 • PharmiWeb
Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Sep 5, 2025 • PharmiWeb
Immunome initiated with a Buy at Craig-Hallum ahead of near-term catalysts
Sep 5, 2025 • thefly.com
Immunome initiated with bullish view at Craig-Hallum
Sep 5, 2025 • thefly.com
Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Sep 4, 2025 • Business Wire
Immunome to Present at the H.C. Wainwright 27th Annual Global Investment Conference
Sep 4, 2025 • BioSpace
Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Sep 4, 2025 • Morningstar.com
Immunome to Present at the H.C. Wainwright 27th Annual Global Investment Conference
Sep 3, 2025 • PharmiWeb
Immunome, Inc. (IMNM) Stock Analysis: A Biotech Bet With 143% Upside Potential
Aug 22, 2025 • DirectorsTalk Interviews
This Netgear Analyst Begins Coverage On A Bullish Note; Here Are Top 4 Initiations For Friday
Aug 22, 2025 • Benzinga.com
Immunome: SpringWorks Buyout Informs The Potential Upside Here (NASDAQ:IMNM)
Aug 11, 2025 • Seeking Alpha
Growth Investors: Industry Analysts Just Upgraded Their Immunome, Inc. (NASDAQ:IMNM) Revenue Forecasts By 73%
Aug 9, 2025 • Yahoo Finance
Immunome Reports Second Quarter 2025 Financial Results and Provides Business Update
Aug 6, 2025 • Yahoo Finance
Immunome Reports Second Quarter 2025 Financial Results and Provides Business Update
Aug 6, 2025 • Business Wire
Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - August 1, 2025
Aug 3, 2025 • BioSpace
Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Aug 1, 2025 • Morningstar.com
Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Aug 1, 2025 • MarketScreener
Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Aug 1, 2025 • Business Wire
Bullish Immunome Insiders Loaded Up On US$3.84m Of Stock
Jul 17, 2025 • simplywall.st
Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Jul 3, 2025 • MarketScreener
Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Jul 3, 2025 • Business Wire
Immunome (IMNM) Soars 6.0%: Is Further Upside Left in the Stock?
Jul 1, 2025 • Yahoo Finance
The Neutralizing Antibody Report 2025 – For Strategy Officers and Market Intelligence Teams
Jul 1, 2025 • EIN Presswire
Immunome, Inc. (IMNM) Stock Analysis: Exploring a 177% Potential Upside in Biotechnology
Jun 20, 2025 • DirectorsTalk Interviews
Immunome (IMNM) Upgraded to Buy: Here's What You Should Know
Jun 16, 2025 • Nasdaq